Biopharma News

Dec 11, 2017
By BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Dec 08, 2017
By BioPharm International Editors
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
Dec 04, 2017
By BioPharm International Editors
The acquisition deepens Astellas’ involvement in the development of a pipeline of therapeutics focused on mitochondrial function.
Dec 04, 2017
By BioPharm International Editors
FDA has approved Mylan’s biosimilar to Roche’s blockbuster anti-cancer biologic, Herceptin.
Dec 01, 2017
By BioPharm International Editors
The company has opened a new California facility that, combined with its existing site in Foster City, CA, will quadruple its laboratory footprint for gene therapy products.
Nov 28, 2017
By BioPharm International Editors
The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.
Nov 20, 2017
By BioPharm International Editors
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
Nov 20, 2017
By BioPharm International Editors
Ontruzant is the first biosimilar of Roche’s Herceptin (trastuzumab) to be approved in Europe.
Nov 20, 2017
By BioPharm International Editors
The opnME.com platform offers scientists access to best-in-class molecules supported by comprehensive data packages.
Nov 16, 2017
By BioPharm International Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
native1_300x100
lorem ipsum